Menu
Search
|

Menu

Close
X

Athersys Inc ATHX.OQ (NASDAQ Stock Exchange Capital Market)

2.02 USD
-0.03 (-1.46%)
As of 1:30 AM IST
chart
Previous Close 2.05
Open 2.05
Volume 44,402
3m Avg Volume 173,825
Today’s High 2.07
Today’s Low 2.02
52 Week High 3.08
52 Week Low 1.29
Shares Outstanding (mil) 113.91
Market Capitalization (mil) 275.67
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
1
FY17
4
FY16
17
FY15
12
EPS (USD)
FY18
-0.080
FY17
-0.284
FY16
-0.180
FY15
-0.205
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
80.30
5.73
Price to Book (MRQ)
vs sector
10.52
5.45
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.72
LT Debt to Equity (MRQ)
vs sector
0.00
12.39
Return on Investment (TTM)
vs sector
-103.95
14.61
Return on Equity (TTM)
vs sector
-109.33
16.34

EXECUTIVE LEADERSHIP

Gil Van Bokkelen
Chairman of the Board, Chief Executive Officer, Since 2000
Salary: $484,500.00
Bonus: $154,071.00
William Lehmann
President, Chief Operating Officer, Since 2006
Salary: $396,780.00
Bonus: $96,417.00
John Harrington
Executive Vice President, Chief Scientific Officer, Director, Since 2007
Salary: $394,740.00
Bonus: $96,632.00
Laura Campbell
Senior Vice President - Finance, Since 2016
Salary: $270,000.00
Bonus: $51,691.00
Lee Babiss
Lead Independent Director, Since 2013
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3201 Carnegie Ave
CLEVELAND   OH   44115-2634

Phone: +1216.4319900

Athersys, Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company's MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients. In the neurological area, the Company evaluated in a completed Phase II trial, the potential for MultiStem treatment of patients with a history of neurological damage from an ischemic stroke. The Company initiated a Phase II clinical study in the United States for the administration of MultiStem cell therapy to patients with a history of an acute myocardial infarction, or AMI.

SPONSORED STORIES